Red clover extract exerts antidiabetic and hypolipidemic effects in db/db mice

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 699-704

  Qiu, Longxin ^a   Chen, Tong ^a   Zhong, Fojin ^a   Hong, Yamin ^a   Chen, Limei ^a   Ye, Hong ^a  

^a LONGYAN UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Fatty acid synthase; Lipid homeostasis; Peroxisome proliferator activated receptors; Red clover extract; Type

Indexed keywords

ACETYL COENZYME A; ACETYL COENZYME A OXIDASE; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; BIOCHANIN A; CARNITINE PALMITOYLTRANSFERASE I; CD36 ANTIGEN; CHOLESTEROL; DAIDZEIN; FATTY ACID SYNTHASE; FORMONONETIN; GENISTEIN; GLUCOKINASE; GLUCOSE; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RED CLOVER EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DYSLIPIDEMIA; GENE EXPRESSION; GENE TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; LIPID BLOOD LEVEL; LIPOGENESIS; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RED CLOVER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84865355087     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.658     Document Type: Article

References (32)

1. Wong MC, Emery PW, Preedy VR and Wiseman H: Health benefits of isoflavones in functional foods? Proteomic and metabonomic advances. Inflammopharmacology 16: 235-239, 2008.
2. Usui T: Pharmaceutical prospects of phytoestrogens. Endocr J 53: 7-20, 2006.
3. Bhathena SJ and Velasquez MT: Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76: 1191-1201, 2002.
4. Lee JS: Effects of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. Life Sci 79: 1578-1584, 2006.
5. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA and ShayN: Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133: 1238-1243, 2003.
6. Jayagopal V, Albertazzi P, Kilpatrick ES, et al: Beneficial effects of soy phytoestrogen intake in postmenopausal women with type2 diabetes. Diabetes Care 25: 1709-1714, 2002.
7. Li Z, Hong K, Saltsman P, et al: Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese typeII DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein. Eur J Clin Nutr 59: 411-418, 2005.
8. Gobert CP, Pipe EA, Capes SE, Darlington GA, Lampe JW and DuncanAM: Soya protein does not affect glycaemic control in adults with type 2 diabetes. Br J Nutr 103: 412-421, 2009.
9. González S, Jayagopal V, Kilpatrick ES, Chapman T and AtkinSL: Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. Diabetes Care 30: 1871-1873, 2007.
10. Qiu L, Ye H, Chen L, Hong Y, Zhong F and Zhang T: Red clover extract ameliorates dyslipidemia in streptozotocin-induced diabetic C57BL/6 mice by activating hepatic PPARα. Phytother Res 26: 860-864, 2012.
11. Kota BP, Huang TH and Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85-94, 2005.
12. Shen P, Liu MH, Ng TY, Chan YH and Yong EL: Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J Nutr 136: 899-905, 2006.
13. Inoue M, Ohtake T, Motomura W, et al: Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336: 215-222, 2005.
14. Kim SY, Kim HI, Park SK, et al: Liver glucokinase can be activated by peroxisome proliferator-activated receptor-gamma. Diabetes 53 (Suppl 1): S66-S70, 2004.
15. Mueller M, Hobiger S and Jungbauer A: Red clover extract: a source for substances that activate peroxisome proliferator-activated receptor alpha and ameliorate the cytokine secretion profile of lipopolysaccharide-stimulated macrophages. Menopause 17: 379-387, 2010.
16. Qiu L, Lin B, Lin Z, Lin Y, Lin M and Yang X: BiochaninA ameliorates the cytokine secretion profile of lipopolysaccharide-stimulated macrophages by a PPARγ-dependent pathway. Mol Med Report 5: 217-222, 2012.
17. Guo L and Tabrizchi R: Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther 111: 145-173, 2006.
18. Ronis MJ, Chen Y, Badeaux J and Badger TM: Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling. J Nutr 139: 1431-1438, 2009.
19. Asgary S, Moshtaghian J, Naderi G, et al: Effects of dietary red clover on blood factors and cardiovascular fatty streak formation in hypercholesterolemic rabbits. Phytother Res 21: 768-770, 2007.
20. Geller SE and Studee L: Soy and red clover for mid-life and aging. Climacteric 9: 245-263, 2006.
21. Lukaczer D, Darland G, Tripp M, et al: Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: a pilot trial. Altern Ther Health Med 11: 60-65, 2005.
22. Schult TM, Ensrud KE, Blackwell T, Ettinger B, WallaceR and TiceJA: Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas 48: 209-218, 2004.
23. Haines C, James A, Sahota D, et al: Comparison between phytoestrogens and estradiol in the prevention of atheroma in ovariectomized cholesterol-fed rabbits. Climacteric 9: 430-436, 2006.
24. Howes JB, Sullivan D, Lai N, et al: The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 152: 143-147, 2000.
25. Lefebvre P, Chinetti G, Fruchart JC and Staels B: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116: 571-580, 2006.
26. Auwerx J, Schoonjans K, Fruchart JC and StaelsB: Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124 (Suppl): S29-S37, 1996.
27. Vu-Dac N, Gervois P, Jakel H, et al: Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278: 17982-17985, 2003.
28. Qiu L, Wu X, Chau JF, et al: Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis. J Biol Chem 283: 17175-17183, 2008.
29. Semenkovich CF: Regulation of fatty acid synthase (FAS). Prog Lipid Res 36: 43-53, 1997.
30. Horton JD and Shimomura I: Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 10: 143-150, 1999.
31. Horton JD, Goldstein JL and Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131, 2002.
32. Shin ES, Lee HH, Cho SY, Park HW, Lee SJ and LeeTR: Genistein downregulates SREBP-1 regulated gene expression by inhibiting site-1 protease expression in HepG2 cells. J Nutr 137: 1127-1131, 2007.